A human THY1 promoter and a human APP sequence carrying mutations found in Alzheimer's disease patients (Swedish double mutation K670M and N671L and London mutation V717I) was used for the transgene. In situ hybridization analysis of brain sections from transgenic animals showed the highest levels of transgene expression in the neocortex and hippocampus.